Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 5/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | FPR3 | P25089 | 1/20 | 0.37 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.37 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.37 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6765200 | 1.00 | CCR1 (0.44) | CCR1TSHREPHX2SCN9APTGER4 | |
| SCHEMBL6765181 | 0.90 | NPC1 (0.47) | CCR1TSHREPHX2NPC1RAB9A | |
| SCHEMBL6765183 | 0.90 | NPC1 (0.47) | CCR1TSHREPHX2NPC1RAB9A | |
| SCHEMBL6763128 | 0.90 | CCR1 (0.42) | CCR1TSHREPHX2SCN9A | |
| SCHEMBL6763125 | 0.90 | CCR1 (0.42) | CCR1TSHREPHX2SCN9A | |
| SCHEMBL6762007 | 0.89 | CCR1 (0.52) | CCR1TSHREPHX2PTGER4LMNA | |
| SCHEMBL6762010 | 0.89 | CCR1 (0.52) | CCR1TSHREPHX2PTGER4LMNA | |
| SCHEMBL6761308 | 0.89 | CCR1 (0.48) | CCR1TSHREPHX2PTGER4NPC1 | |
| SCHEMBL6758137 | 0.89 | CCR1 (0.45) | CCR1TSHREPHX2PTGER4 | |
| SCHEMBL6761312 | 0.89 | CCR1 (0.48) | CCR1TSHREPHX2PTGER4NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063688-A1 | Novel piperidine derivatives | PFIZER INC. | 2004-04-01 | — | — | US | claimed |
| US-20040063688-A1 | Novel piperidine derivatives | PFIZER INC. | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063688-A1 | Novel piperidine derivatives | CCR1, CCR3, CCR2 | CCR1 1/4885TSHR 2865/4885EPHX2 3279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.